Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study

Abstract

BackgroundThe phase II NIVOREN GETUG-AFU 26 study reported safety and efficacy of nivolumab in patients with metastatic clear cell renal cell carcinoma (m-ccRCC) in a ‘real-world setting’. We conducted a translational-research program to determine whether specific circulating immune-cell populations and/or soluble factors at baseline were predictive of clinical outcomes in patients with m-ccRCC treated with nivolumab within the NIVOREN study.MethodsAbsolute numbers of 106 circulating immune-cell populations were prospectively analyzed in patients treated at a single institution within the NIVOREN trial with available fresh-whole-blood, using dry formulation panels for multicolor flow cytometry. In addition, a panel of 14 predefined soluble factors was quantified for each baseline plasma sample using the Meso-Scale-Discovery immunoassay. The remaining patients with available plasma sample were used as a validation cohort for the soluble factor quantification analysis. Tumor immune microenvironment characterization of all patients included in the translational program of the study was available. The association of blood and tissue-based biomarkers, with overall survival (OS), progression-free survival (PFS) and response was analyzed.ResultsAmong the 44 patients, baseline unswitched memory B cells (NSwM B cells) were enriched in responders (p=0.006) and associated with improved OS (HR=0.08, p=0.002) and PFS (HR=0.54, p=0.048). Responders were enriched in circulating T follicular helper (Tfh) (p=0.027) and tertiary lymphoid structures (TLS) (p=0.043). Circulating NSwM B cells positively correlated with Tfh (r=0.70, p<0.001). Circulating NSwM B cells correlated positively with TLS and CD20 +B cells at the tumor center (r=0.59, p=0.044, and r=0.52, p=0.033) and inversely correlated with BCA-1/CXCL13 and BAFF (r=−0.55 and r=−0.42, p<0.001). Tfh cells also inversely correlated with BCA-1/CXCL13 (r=−0.61, p<0.001). IL-6, BCA-1/CXCL13 and BAFF significantly associated with worse OS in the discovery (n=40) and validation cohorts (n=313).ConclusionWe report the first fresh blood immune-monitoring of patients with m-ccRCC treated with nivolumab. Baseline blood concentration of NSwM B cells was associated to response, PFS and OS in patients with m-ccRCC treated with nivolumab. BCA-1/CXCL13 and BAFF, inversely correlated to NSwM B cells, were both associated with worse OS in discovery and validation cohorts. Our data confirms a role for B cell subsets in the response to immune checkpoint blockade therapy in patients with m-ccRCC. Further studies are needed to confirm these findings.

Circulating plasmablasts and follicular helper T-cell subsets are associated with antibody-positive autoimmune epilepsy

“…It has recently been reported that an increase in USM in the peripheral circulation is associated with IgG1/IgM responses to SARS-CoV2 results in earlier COVID-19 recovery ( 39 ). Furthermore, a parallel increase in circulating USM with cTfh has been reported in cancer patients who respond well to immune checkpoint therapy ( 40 ). Such an immune response in infection and cancer, in turn, potentially suggests an association between USM and cTfh in the autoimmune response in patients with NSA.…”

The relationship between immune cells and prostate cancer, and the mediating role of metabolites: a Mendelian randomization study

“…Conversely, unswitched memory cells are considered a non-classical type of memory B cells, and their origin in humoral immunity is controversial [21]. A related study investigated the impact of nivolumab on the treatment of renal clear cell carcinoma, and the results showed that unswitched memory cells played a positive role in the overall survival and progression-free survival of patients with renal clear cell carcinoma, this cell state is called the peripheral imprint of TME [22]. Our research provides a new perspective on PCa treatment by showing that unswitched memory B cells play a positive role in PCa risk.…”

Exploration of the immunogenetic landscape of hyperprogressive disease after combined immunotherapy in cancer patients

“…However, IL-17A, a cytokine with a similar function to IL-6, was not similarly elevated in the non-HPD group after immunotherapy. IL-6, an immune inflammatory cytokine involved in immune cell development, has been shown to be associated with worse survival after treatment with anti-PD-1 therapy, 22 , 23 poorer treatment response, 24 and higher risk of immune-related adverse events. 25 IL-6 in the TiME is produced by cancer cells, host stromal cells, or tumor-infiltrating immune cells such as macrophages.…”